First Hepatitis B Patients Treated in Study of New Therapy at Lower Doses Than Standard
ContraVir Pharmaceuticals announced the dosing of the first patients with chronic hepatitis B enrolled in its head-to-head Phase 2a clinical trial comparing multiple doses of the company’s lead candidate CMX157 to tenofovir disoproxil fumarate (TDF), a standard therapy. Specifically, the trial will compare a lower dose of CMX157 to the commonly used dose of TDF (Viread, Gilead Sciences).
NASH May Be Prevented in Hepatitis Patients by Blocking Inflammatory Cytokine
The proinflammatory cytokine IL-17 drives the development of non-alcoholic steatohepatitis, or NASH — a disease that often leads to liver cancer, researchers at the National Cancer Research Centre (CNIO), in Spain, reported.
Liver sinusoidal endothelial cells: physiology and role in liver diseases
Liver sinusoidal endothelial cells (LSECs) are highly specialized endothelial cells representing the interface between blood cells on the one side and hepatocytes and hepatic stellate cells on the other side.
Combined systemic elimination of MET and EGFR signaling completely abolishes liver regeneration and leads to liver decompensation.
Receptor tyrosine kinases MET and EGFR are critically involved in initiation of liver regeneration. Other cytokines and signaling molecules also participate in the early part of the process. Regeneration employs effective redundancy schemes to compensate for the missing signals. Elimination of any single extracellular signaling pathway only delays but does not abolish the process.
Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
The pathomechanisms underlying non-alcoholic fatty liver disease (NAFLD) and the involved molecular regulators are incompletely explored. The nuclear factor-kappa B (NFκB)-cofactor gene B-cell leukemia-3 (bcl-3) plays a critical role in altering the transcriptional capacity of NFκB - a key inducer of inflammation - but also of genes involved in cellular energy metabolism.
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012
Delayed HBV or HCV diagnosis may increase risk of advanced liver disease complications, including decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC). The aim of this study was to characterise “late hepatitis notification” among people with an HBV/HCV notification and advanced liver disease in New South Wales, Australia.
Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis
Nonalcoholic fatty liver disease (NAFLD) has been associated with subclinical atherosclerosis in cross-sectional studies. We investigated the longitudinal association of NAFLD with the development of subclinical carotid atherosclerosis.
Functional imaging in liver tumours
Functional imaging encompasses techniques capable of assessing physiological parameters of tissues, and offers useful clinical information in addition to that obtained from morphological imaging.
Exercise in NAFLD: Just do it
The health burden of non-alcoholic fatty liver disease (NAFLD) is multifaceted. In addition to sequelae of end-stage liver disease and hepatocellular carcinoma, the deleterious role of hepatic steatosis in the development of type 2 diabetes and cardiovascular disease is also well established.
Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma
We read with great interest the article by Reig et al., published in Journal of Hepatology, which reported the impact of direct acting antivirals (DAA) on the risk of hepatocellular carcinoma (HCC) recurrence after achievement of complete radiological response by resection, ablation or chemoembolization.